Department of Neurosurgery, Queen's Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Neurosurgery. 2019 Oct 1;85(4):486-493. doi: 10.1093/neuros/nyy366.
Drain insertion following chronic subdural hematoma (CSDH) evacuation improves patient outcomes.
To examine whether this is influenced by variation in drain location, positioning or duration of placement.
We performed a subgroup analysis of a previously reported multicenter, prospective cohort study of CSDH patients performed between May 2013 and January 2014. Data were analyzed relating drain location (subdural or subgaleal), position (through a frontal or parietal burr hole), and duration of insertion, to outcomes in patients aged >16 yr undergoing burr-hole drainage of primary CSDH. Primary outcomes comprised modified Rankin scale (mRS) at discharge and symptomatic recurrence requiring redrainage within 60 d.
A total of 577 patients were analyzed. The recurrence rate of 6.7% (12/160) in the frontal subdural drain group was comparable to 8.8% (30/343) in the parietal subdural drain group. Only 44/577 (7.6%) patients underwent subgaleal drain insertion. Recurrence rates were comparable between subdural (7.7%; 41/533) and subgaleal (9.1%; 4/44) groups (P = .95). We found no significant differences in discharge mRS between these groups. Recurrence rates were comparable between patients with postoperative drainage for 1 or 2 d, 6.4% and 8.4%, respectively (P = .44). There was no significant difference in mRS scores between these 2 groups (P = .56).
Drain insertion after CSDH drainage is important, but position (subgaleal or subdural) and duration did not appear to influence recurrence rate or clinical outcomes. Similarly, drain location did not influence recurrence rate nor outcomes where both parietal and frontal burr holes were made. Further prospective cohort studies or randomized controlled trials could provide further clarification.
慢性硬脑膜下血肿(CSDH)清除术后引流可改善患者预后。
研究引流位置、置管位置和置管时间的变化是否会影响这一结果。
我们对 2013 年 5 月至 2014 年 1 月进行的一项多中心前瞻性队列研究中的 CSDH 患者进行了亚组分析。分析数据与年龄>16 岁的患者有关,这些患者接受了原发性 CSDH 的颅骨钻孔引流术,分析内容包括引流位置(硬脑膜下或皮下)、位置(通过额骨或顶骨骨孔)以及置管时间与患者出院时改良 Rankin 量表(mRS)评分和 60 天内需要再次引流的症状性复发的关系。
共分析了 577 例患者。额骨硬脑膜下引流组的复发率为 6.7%(12/160),与顶骨硬脑膜下引流组的 8.8%(30/343)相似。仅有 44/577(7.6%)例患者行皮下引流。硬脑膜下引流(7.7%,41/533)和皮下引流(9.1%,4/44)组之间的复发率无显著差异(P=0.95)。两组患者出院时 mRS 评分无显著差异。术后引流 1 或 2 天的患者复发率分别为 6.4%和 8.4%,差异无统计学意义(P=0.44)。这两组患者 mRS 评分无显著差异(P=0.56)。
CSDH 引流后引流很重要,但位置(皮下或硬脑膜下)和持续时间似乎不会影响复发率或临床结果。同样,在同时开颅顶骨和额骨骨孔的情况下,引流位置也不会影响复发率或结果。进一步的前瞻性队列研究或随机对照试验可能会提供进一步的澄清。